Search

Your search keyword '"Anthoney A"' showing total 1,140 results

Search Constraints

Start Over You searched for: Author "Anthoney A" Remove constraint Author: "Anthoney A"
1,140 results on '"Anthoney A"'

Search Results

1. Testicular salvageability and its predictors among patients with testicular torsion in a resource limited setting: a multicentre longitudinal study

4. Multisystem Inflammatory Syndrome in Children

5. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

6. 2023 FORCE Development Status Update

7. NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

10. Transcranial ultrasound neuromodulation of the thalamic visual pathway in a large animal model and the dose-response relationship with MR-ARFI

11. Predicting Delayed Shock in Multisystem Inflammatory Disease in Children: A Multicenter Analysis From the New York City Tri-State Region

12. 'Working Together Is Like a Partnership of Entangled Knowledge': Exploring the Sensitivities of Doing Participatory Data Analysis with People with Learning Disabilities

15. Functional analysis of the toll receptor protein family and their downstream signaling pathways in the central nervous system of Drosophila

16. Attachment Styles and their Demographic Association Among Adult Children of Alcoholic Fathers in Pakistan

18. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

19. Multisystem Inflammatory Syndrome in Children

20. Patients’ perspectives on factors facilitating adherence to tuberculosis treatment in Iquitos, Peru: a qualitative study

21. Impact of firefighter hood design on range of motion, noise production and hearing.

22. Impact of Durable Water-Repellent Finishing in Thermal Liner on Firefighter Heat Stress.

23. The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction

24. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

25. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

26. Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study

28. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

32. The neuronal ceroid lipofuscinosis protein Cln7 functions in the postsynaptic cell to regulate synapse development

35. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’

38. Baclofen Withdrawal Presenting as Irritability in a Developmentally Delayed Child

39. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

40. A Toll-receptor map underlies structural brain plasticity

41. Machinic enculturation, copyright bots, and the aesthetics of composing mashups for machines

42. Development of a combined paediatric emergency department and observation unit

43. Preventing malaria in the Peruvian Amazon: a qualitative study in Iquitos, Peru

44. Mean plasma SRA737 concentration over time from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

45. Mean exposure (AUC0–12) by dose level from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

46. Data from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

47. Supplementary Methods. MS1 from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

48. Demographic and Disease Characteristics from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

49. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

50. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Catalog

Books, media, physical & digital resources